Microdosing MDMA for Health & Longevity - Quick Reference Sheet

Microdosing MDMA for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

MDMA is a synthetic compound, known illicitly as ecstasy, used in supervised therapy for severe trauma; microdosing means repeating amounts too small to be felt, for steadier mood, easier social connection, and more motivation. That practice has essentially never been tested. Small amounts still raise blood pressure and heart rate, briefly blunt memory, and can be dangerous alongside common antidepressants. Lasting benefits remain reported rather than demonstrated. (Full Review)

Protocol

Community microdosing schedule
5 to 25 mg
No validated dosing protocol exists; circulating schedules are adapted from classic psychedelics.
Best time of day
Morning
Single morning dose. MDMA is stimulant at every dose, suppresses REM sleep, and delays sleep onset.
Half-life and its practical implication
No more than weekly
Clearance takes 36 to 48 hours; the enzyme inhibition it causes lasts several days.
Time to effect
Acute onset
30 to 60 minutes
Begins within 30 to 60 minutes of an oral dose.
Acute peak
90 to 120 minutes
Any perceptible effect is apparent on the first dosing day.
Claimed cumulative benefits
No established time course
No controlled study has measured them; in other compounds self-reported benefit is suggested within two weeks.

Benefits

Contraindications
  • Monoamine oxidase inhibitors, or within 14 days of stopping
  • Uncontrolled hypertension (at or above 160/100 mmHg)
  • Moderate or greater valvular regurgitation or stenosis
  • Coronary or structural heart disease, or heart attack within 12 months
  • Serious arrhythmia or long QT syndrome, any history
  • Liver impairment of Child-Pugh Class B or C
  • Kidney function below 30 mL/min/1.73 m²
  • Psychosis or bipolar I disorder, personal or first-degree relative
  • Prior MDMA-associated hyponatremia, or SIADH
  • Pregnancy and breastfeeding
  • Any current substance use disorder
  • Relative: well-controlled hypertension, serotonergic medication within six weeks, CYP2D6 poor metabolizer
Key Interactions
  • Serotonergic antidepressants (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, duloxetine)
  • Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine, terbinafine, ritonavir)
  • Other serotonergic drugs (tramadol, triptans, lithium, buspirone, linezolid)
  • Over-the-counter (dextromethorphan, pseudoephedrine, phenylephrine, NSAIDs)
  • Serotonergic supplements (5-HTP, L-Tryptophan, St. John's wort, SAMe)
  • Cardiovascular supplements (caffeine, yohimbine, synephrine, high-dose green tea extract)
  • Other interventions (sauna, hot yoga, high-intensity training, alcohol)

Risk & Side Effects

  • High: Dose-dependent cardiovascular stimulation; acute memory and cognitive-control impairment; serotonin toxicity with serotonergic drugs; unpredictable content and dose of illicit material
  • Medium: Post-dose mood dip and sleep disruption; rapid tolerance; bruxism, appetite suppression, and other autonomic effects; non-linear pharmacokinetics causing unintended escalation
  • Low: Serotonergic neurotoxicity from cumulative exposure (conflicted); hyponatremia; hepatotoxicity; dependence, compulsive use, and escalation; transient immune suppression
  • Speculative: Valvular heart disease and cardiac fibrosis; accelerated vascular aging; long-term neuroendocrine dysregulation

Monitoring

Marker Target Why
Resting blood pressure 105–120 / 65–78 mmHg Detects the compound's most consistent physiological effect
Resting heart rate 50–65 bpm Tracks arousal load and recovery between doses
Serum sodium 138–142 mmol/L Screens for the water retention that produces hyponatremia
ALT 10–26 U/L in men, 9–22 U/L in women Earliest signal of strain on the liver, which clears this compound
GGT Under 20 U/L in men, under 15 U/L in women Liver and oxidative stress, and alcohol co-exposure
eGFR (estimated glomerular filtration rate) Above 90 mL/min/1.73 m² Kidney function governs both sodium handling and metabolite clearance
hs-CRP Under 0.8 mg/L Background marker of body-wide inflammation, not drug-specific
Echocardiogram (ultrasound of the heart) No more than trace mitral, aortic, or tricuspid regurgitation; no leaflet thickening The only way to detect valve changes from chronic serotonin-receptor stimulation
CYP2D6 genotype Normal metabolizer phenotype Determines whether a nominal microdose gives microdose-level exposure

Cadence: Blood pressure and heart rate before and roughly two hours after each of the first four doses, then weekly for three months, then monthly; serum sodium, liver enzymes, and kidney function at 3 and 6 months, then every 6 months; hs-CRP every 6 to 12 months; echocardiography at baseline and every 12 months for anyone dosing more often than monthly beyond a year, or sooner if a new murmur, exertional breathlessness, or unexplained fatigue appears.

Qualitative Assessment

  • Sleep quality: onset latency, total sleep time, and overnight heart rate variability on dosing nights
  • Mood trajectory across the full dosing cycle: rated daily, since the signal is whether the post-dose dip cancels the on-dose lift
  • Cognitive clarity and work output: an objective proxy such as deep-work hours or a repeated reaction-time and working-memory task
  • Social engagement: frequency and quality of unprompted social contact
  • Physical side-effect burden: jaw tension, appetite on dosing days, and any dental or jaw-joint symptoms
  • Escalation signals: any dose or frequency increase beyond the plan, or reluctance to take a scheduled break